My hunch is that the share price will get to at least $2.50 upon announcement of NDA filing with the FDA. That equates to a MC of approx $385 million. Between now and then we may hear of more KOLs being onboarded as prescribers and prescriptions issued to keep up with strong demand as part of the growth plan under the SAS in AU. There is then potential news of exploring further indication that could be treated. Of course, nothing is guaranteed so these are just my musings.
Ann: LTP Secures Global CoDevelopment Agreement with Aptar Pharma, page-29
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.78M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.0¢ | 27.5¢ | $85.42K | 310.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15746 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 43164 | 5 |
View Market Depth
| Last trade - 12.40pm 25/06/2025 (20 minute delay) ? |
| LTP (ASX) Chart |